The method and apparatus relate to non-invasive aesthetic treatment procedures and in particular to body shaping, skin treatment and other aesthetic treatments.
Body shaping, skin tightening and rejuvenation, collagen fibers contraction, removal of wrinkles, and other aesthetic skin treatments are popular and widely used in the field of cosmetic and appearance improvement procedures. The treatments are typically provided through the application of electromagnetic or acoustic energy to a target section of skin. In these treatment procedures, an applicator having an inner cavity or vacuum chamber is typically applied to the skin of a subject such that the section of the skin to be treated is pulled up or drawn into the vacuum chamber forming a skin fold that will be termed as skin protrusion. The electromagnetic energy, such as Radio Frequency (RF), or acoustic energy, such as ultrasound, is applied to one or more sides of the protrusion to perform a desired skin/tissue effect in the skin/tissue between the electrodes or between ultrasound transducers. After the treatment, the skin is again straightened or the protrusion is relaxed and the desired skin effect such as, for example contraction of collagen fibers or destruction of adipose tissue by the electromagnetic or acoustic energy, is realized.
The generation of the skin protrusion includes multiple advantages, one such being that it allows all or portions of the skin to be treated by rapidly conforming to the shape of the applicator and preventing undesired movement of the applicator during the treatment. Formation of the protrusion and negative pressure in the cavity is also necessary to stabilize and temporarily attach energy emitting contact surfaces to the skin. Properly attached electrodes couple larger portions of RF or ultrasound and increase the desired treatment effects, reduce the number of treatments required to reach the desired effect, and improve the success confidence of the treated subject. However, to ensure proper contact with the skin, the vacuum that is applied to the skin should be strong enough to form and maintain the protrusion. However, the application of sufficient vacuum force to provide the desired contact has some negative effects on the skin. These negative effects can include, among other things, leaving endemic bruising spots on the skin, causing pain to the treated subject during the procedure and following, and requiring extended post-treatment recovery periods.
The vacuum chamber or cavity used for protrusion formation has a relatively large size but, the skin drawn inside may occupy only a section of the cavity. The pump that delivers vacuum or negative pressure into the chamber should be a relatively large pump enabling rapid air evacuation from the cavity, protrusion formation and maintaining of the protrusion for at least the time of treatment. These requirements unfortunately increase the cost of the equipment used for different skin treatment procedures because, there is variability in the skin properties between different subjects. In addition, because of this, low-level vacuum pressure or force is sufficient for generation of the required protrusion for some treated subjects. However, other subjects may require a substantially higher level of vacuum force. It is a common practice of the caregiver or operator to manually adjust or vary the vacuum level, until he or she finds the optimal level, which is sufficient for the treatment of the skin and does not cause painful sensations. This optimal vacuum level varies from one subject to the other, sometimes there is no such optimal level, and the treatment is either painful or inefficient.
It would be desirable to have an applicator that would allow a protrusion to be formed and maintained for a desired time with good coupling to the energy emitting surfaces, without adversely affecting the skin or causing pain to the treated subject.
Described is an applicator for RF, ultrasound, and light skin treatment. The applicator includes a cavity operatively configured to receive into it a segment of skin to be configured as a protrusion and a valve. The cavity communicates with a source of negative pressure. The protrusion applies pressure to the valve and displaces the valve in the cavity. The valve displacement regulates the negative pressure in the cavity.
RF energy, ultrasound or light energy may be applied to the skin protrusion at different overlapping and none overlapping periods to cause the desired treatment effect.
The applicator allows a protrusion to be formed and maintained for a desired time, enables good coupling of the treatment energy with the skin and avoids negative pressure adversely affecting the skin.
The applicator and method of the applicator use are particularly indicated and distinctly claimed in the concluding portion of the specification. The applicator and the method, however, both as to organization and method of operation, may best be understood by reference to the following detailed description when read with the accompanied drawings, in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the method.
In the following detailed description, for purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the present applicator, principles of the applicator operation and method of using the applicator. It will be apparent, however, that the present applicator and method may be practiced without these specific details. In this regard, directional terminology, such as “up,” “down,” “front,” “back,” etc., is used with reference to the orientation of the Figure(s) being described. Because components of embodiments of the present invention can be positioned in a number of different orientations, the directional terminology is used for purposes of illustration and is in no way limiting.
Reference is made to
A rim 124 terminates the second end of applicator 100. Rim 124 may have a thickness similar to the walls 128 of applicator 100 housing 104; it may terminate by a gasket, or have a surface (
Pump 116 continues to operate and protrusion 208 expands further occupying almost all volume of cavity 108. As protrusion 208 expands it contacts plate 140 of valve 120, displaces or pushes the plate, and components of valve 120 associated with it in the direction indicated by arrow 212 (
As the time passes, air gradually leaks into cavity 108 of applicator 100. The value of the negative pressure diminishes, and protrusion 208 reduces its magnitude or volume and recedes. Forces generated by spring 152 maintain permanent contact of plate 140 with protrusion 208 and return plate 140 and associated with plate 140, parts of valve 120 to the original location or to a section of the stroke. Spring 152 develops relatively gentle force that pushes down plate 140. For example, if the pump 116 generates a negative pressure of 0.6 Bar and the cross section of the valve is 0.2 cm2, the force would be 1.2N. Such gentle pressure required for formation of the protrusion is relatively low and does not generate adverse effects in or on the skin.
Valve 120 operated by positive pressure developed by skin protrusion 208 and spring 152 forces, acts like an ON-OFF switch enabling or disabling communication with pump 116. Actually, protrusion 208 automatically regulates its magnitude by regulating the level of the negative pressure developed by pump 116, forcing protrusion shape and volume optimally for the desired treatment, and enabling firm contact to the surfaces of cavity walls. Excessive negative pressure values are automatically avoided and no damage, pain or other adverse effects are inflicted to the treated skin section. Spring 152 ensures the return path of valve 120 when the action of pump 116 is discontinued, locating valve 120 into a position suitable for the next treatment cycle and/or translation to a new skin section. Thus, the valve operates as a protrusion magnitude detector by switching off the negative pressure when the protrusion reaches a desired or threshold value, which moves the valve to a position to throw the switch.
Protrusion 334 pushes up plate 314 of valve 310 regulating the level of vacuum in the cavity and the protrusion 334 magnitude.
It is known that aesthetic and medical skin treatments are usually accompanied by application of gel to the treated skin surface. The purpose of the gel application may be for the improvement of electrical contact with the skin, improvement of ultrasound to skin coupling, and easier translation of the applicator over the skin. The application of the vacuum force may result in sucking the applied skin gel into the vacuum system. The gel may become an obstacle to proper vacuum system operation it may deposit the gel in undesired places and applicator components. The gel hardens with time, and even may damage the vacuum pump. Applicator 300 is equipped by a gel guard 390 with dimensions tightly fitted to the applicator 300 inner cross section dimensions. In one embodiment, gel guard 390 is a reusable part that should be cleaned from time to time as gel accumulates on it. In another embodiment, gel guard 390 is an easily exchangeable disposable part. The disposable gel guard 390 may include guides 322 and pusher 324 with stopper disk 318, further simplifying gel guard replacement. It should be clear that other applicator constructions are possible, including more than two guides, different valve and gasket locations and structures.
One of the applications of the present applicator is for RF skin treatment.
Safety of the application of RF to a subject's skin is aparamount requirement in every aesthetic and medical RF based treatment. Firm contact between electrodes 404 and protrusion 334 ensure good energy to skin transfer, avoids formation of hot spots on the electrodes, and other adverse effects. Such contact conditions exist only when skin protrusion 334 completely fills cavity 424. Sensing of protrusion magnitude (or status) may provide feedback to controller 462 that controls RF generator 416 supplying RF to electrodes 404. Such “protrusion detector (or sensor)” sends the control system 462 a signal when the tissue fills the cavity into the tissue as required for safe energy application. In one embodiment, shown in
Pump 420 generates negative pressure of about −0.1 bar to −0.9 bars, in cavity 424. The negative pressure or vacuum draws skin or tissue 332 into cavity 424 forming a skin protrusion 334. As skin protrusion 334 growths, it occupies a larger volume of cavity 424, and spreads in a uniform way inside the cavity. The protrusion spreading enables firm contact of skin 332 with electrodes 404. Protrusion 334 pushes plate 314 up such that gasket 318 contacts surface 338 of the vacuum communication channel disabling vacuum communication with pump 420. When the negative pressure in cavity 424 drops down, for example, because of air leakage, protrusion 334 recedes or diminishes. Springs 326 push plate 314 and gasket 318 down, away from surface 338 and enable vacuum pump 420 to communicate once again with cavity 424 and evacuate the air from it.
When firm contact between skin protrusion 334 and electrodes 404 is established, controller 462 switches ON RF generator 416 and RF energy is supplied to target volume 452 of skin 332. Phantom lines 456 illustrate schematically RF induced current flow in skin protrusion 334. This current heats target tissue volume 452 and enables the desired treatment effect, which may be body shaping, skin tightening and rejuvenation, contraction of collagen fibers, removal of wrinkles and other aesthetic skin treatment effects. Proper contact between electrodes 404 and skin protrusion 334 may be detected during the treatment by monitoring skin impedance between electrodes 404 as disclosed in the U.S. Pat. No. 6,889,090 to the same assignee. The lower the skin impedance at the beginning of treatment, the better is the contact between electrodes 404 and skin 432 forming protrusion 334.
Increasing skin temperature by RF induced currents, leads to a change in impedance. Monitoring the skin impedance allows the temperature distribution in the skin to be followed so that the parameters of the treatment may be determined, enabling treatment optimization. Such parameters may include, for example, the time RF is applied to the skin, the pulse duration of the RF energy, the frequency of the RF energy, the power of the RF energy, the delay time between cooling the skin and the application of the RF energy.
Other known impedance monitoring methods may also be applied. Applicator 400 may contain additional devices for temperature monitoring, skin and electrodes cooling, illumination devices for illuminating the treated skin section, and others, as may be required by a particular skin treatment. RF generator 416, vacuum pump 420 and other control and auxiliary units such as a cooling fluid pump, impedance measurement circuit, wiring and tubing not shown for the simplicity of explanation, may be placed in a common controller 462 packaging.
It should be noted that the protrusion sensor can be for other purposes rather then simply as a safety feature preventing undesired energy application to a partial protrusion. For instance, the sensor, as will be explained below, can be used to establish tissue properties and in particular tissue laxity, by measuring the time between the start of vacuum and the time when protrusion reaches its desired magnitude. (The terms “tissue flexibility” and “tissue laxity” occasionally used through the disclosure have the same meaning.)
It has been experimentally discovered that the time of protrusion formation is a function of the treated subject tissue laxity and structure.
Tissue laxity may be a good indicator of the need to perform a tissue pretreatment procedure. Such procedure may be a massage or heat application to soften the treated tissue and make it more suitable for the treatment itself. Thus the method disclosed provides a diagnostic tool for determination of tissue stiffness and indication of the treatment parameters most suitable for the particular tissue.
Transducers 604 may be of conventional type or phased array transducers. Transducers 604 may be located on one or both sides of applicator 600 and typically, as disclosed in United States Patent Publication No. 2007/0038156 to the same assignee, incorporated here in its entirety and are focused to emit energy into the same target treatment volume 452 (
RF generator 420 and ultrasound generator 628 provide energy to respective electrodes and transducers. Vacuum pump 416 generates negative pressure forming skin protrusion 334. Sensing of skin protrusion magnitude (or status) may provide feedback to controller 632 that controls RF generator 420 supplying RF to electrodes 404 and ultrasound generator 628 supplying ultrasound energy to transducers 604. In operation such “protrusion detector (or sensor)” sends the control system 632 a signal when the tissue fills-in the cavity as required for safe energy application into the tissue. The protrusion sensor signal may be used to switch ON and OFF the RF generator 420 and ultrasound generator 628. These and other control and auxiliary units such as a cooling fluid pump, wiring and tubing not shown for the simplicity of explanation, may be placed in a common controller packaging 632.
The RF and ultrasound energy are applied for short time duration, as a pulse or a train of pulses (or several pulses), in order to reduce loss of heat from the ultrasound heated focal tissue volumes by conduction or convection. RF and ultrasound energies may be applied simultaneously or one delayed with respect to the other.
The temperature generated at the focal volumes by the RF and ultrasound energy sources and the time of heating are selected such that adequate heating of the focal volumes is obtained, while heating of surrounding tissues is minimal. Increased temperature of the focal volumes facilitated the mechanical action of ultrasound applied to the same volume and helps in achieving a substantial treatment effect.
A number of embodiments have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the method. Accordingly, other embodiments are within the scope of the following claims:
This is a U.S. Non-provisional application for patent being filed under 35 USC 111 and claiming the priority to the U.S. Provisional application for patent that was filed on Jul. 16, 2008 and assigned Ser. No. 61/081,110. This application incorporates by reference U.S. Pat. No. 6,889,090 and United States Patent Publication No. 2007/0038156.
Number | Name | Date | Kind |
---|---|---|---|
1430354 | Burdick | Sep 1922 | A |
2088780 | Follese | Aug 1937 | A |
2183726 | Sommer et al. | Feb 1939 | A |
2231095 | Sommer et al. | Feb 1941 | A |
2727132 | Hills | Dec 1955 | A |
2824308 | Duncan | Feb 1958 | A |
3088205 | Ellis | May 1963 | A |
D196532 | Facci | Oct 1963 | S |
4016886 | Doss et al. | Apr 1977 | A |
4131021 | Mezrich et al. | Dec 1978 | A |
4182329 | Smit et al. | Jan 1980 | A |
4211230 | Woltosz | Jul 1980 | A |
4228931 | Ruscitti et al. | Oct 1980 | A |
4321926 | Roge | Mar 1982 | A |
D269294 | Rakocy et al. | Jun 1983 | S |
D271015 | Geraets | Oct 1983 | S |
D271199 | Geraets | Nov 1983 | S |
4444190 | Mutzhas | Apr 1984 | A |
D274462 | Rakocy et al. | Jun 1984 | S |
4532924 | Auth et al. | Aug 1985 | A |
4550728 | Runyon et al. | Nov 1985 | A |
4553936 | Wang | Nov 1985 | A |
4686986 | Fenyo et al. | Aug 1987 | A |
4753958 | Weinstein et al. | Jun 1988 | A |
4784135 | Blum et al. | Nov 1988 | A |
4787886 | Cosman | Nov 1988 | A |
4844063 | Clark | Jul 1989 | A |
4867682 | Hammesfahr et al. | Sep 1989 | A |
4869584 | Dion | Sep 1989 | A |
5016999 | Williams | May 1991 | A |
5071418 | Rosenbaum | Dec 1991 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
5195977 | Pollitt | Mar 1993 | A |
5286479 | Garlich et al. | Feb 1994 | A |
5316473 | Hare | May 1994 | A |
5348554 | Imran et al. | Sep 1994 | A |
5353798 | Sieben | Oct 1994 | A |
5381067 | Greenstein et al. | Jan 1995 | A |
5402697 | Brooks | Apr 1995 | A |
5406340 | Hoff | Apr 1995 | A |
5418130 | Platz et al. | May 1995 | A |
5443070 | Mniece | Aug 1995 | A |
5487662 | Kipke et al. | Jan 1996 | A |
5509916 | Taylor | Apr 1996 | A |
5521392 | Kennedy et al. | May 1996 | A |
5564851 | Connely et al. | Oct 1996 | A |
5582476 | Hansen | Dec 1996 | A |
5601526 | Chapelon et al. | Feb 1997 | A |
5611793 | Wilson et al. | Mar 1997 | A |
5628771 | Mizukawa et al. | May 1997 | A |
5642997 | Gregg et al. | Jul 1997 | A |
5658148 | Neuberger et al. | Aug 1997 | A |
5693052 | Weaver | Dec 1997 | A |
5698866 | Doiron et al. | Dec 1997 | A |
5704935 | Pahl et al. | Jan 1998 | A |
5707403 | Grove et al. | Jan 1998 | A |
5722411 | Suzuki et al. | Mar 1998 | A |
5731582 | West | Mar 1998 | A |
5735844 | Anderson et al. | Apr 1998 | A |
5755753 | Knowlton | May 1998 | A |
5769880 | Truckai et al. | Jun 1998 | A |
5814008 | Chen et al. | Sep 1998 | A |
5824023 | Anderson | Oct 1998 | A |
5836999 | Eckhouse et al. | Nov 1998 | A |
5843143 | Whitehurst | Dec 1998 | A |
5868744 | Willmen | Feb 1999 | A |
5871524 | Knowlton | Feb 1999 | A |
5885211 | Eppstein et al. | Mar 1999 | A |
5888198 | Eggers et al. | Mar 1999 | A |
5919219 | Knowlton | Jul 1999 | A |
5949514 | Wargon | Sep 1999 | A |
5954710 | Paolini et al. | Sep 1999 | A |
5961543 | Waldmann | Oct 1999 | A |
5984915 | Loeb et al. | Nov 1999 | A |
5993180 | Westerhof et al. | Nov 1999 | A |
6022316 | Eppstein et al. | Feb 2000 | A |
6024733 | Eggers et al. | Feb 2000 | A |
6030384 | Nezhat | Feb 2000 | A |
6053172 | Hovda et al. | Apr 2000 | A |
6056548 | Neuberger et al. | May 2000 | A |
6063108 | Salansky et al. | May 2000 | A |
6066134 | Eggers et al. | May 2000 | A |
6078830 | Levin et al. | Jun 2000 | A |
6080127 | Li et al. | Jun 2000 | A |
6080391 | Tsuchiya et al. | Jun 2000 | A |
6081934 | Stefanovsky et al. | Jul 2000 | A |
6097976 | Yang et al. | Aug 2000 | A |
6107326 | Jori | Aug 2000 | A |
6113558 | Rosenschein et al. | Sep 2000 | A |
6132701 | Perez et al. | Oct 2000 | A |
6142939 | Eppstein et al. | Nov 2000 | A |
6148232 | Avrahami | Nov 2000 | A |
6186960 | Tripp et al. | Feb 2001 | B1 |
6188407 | Smith et al. | Feb 2001 | B1 |
6190609 | Chapman et al. | Feb 2001 | B1 |
6191110 | Jaynes et al. | Feb 2001 | B1 |
6208881 | Champeau | Mar 2001 | B1 |
6210402 | Olsen et al. | Apr 2001 | B1 |
6221095 | Van Zuylen et al. | Apr 2001 | B1 |
6228078 | Eggers et al. | May 2001 | B1 |
6231571 | Ellman et al. | May 2001 | B1 |
6231593 | Meserol | May 2001 | B1 |
6251127 | Biel | Jun 2001 | B1 |
6256525 | Yang et al. | Jul 2001 | B1 |
6258319 | Hearst et al. | Jul 2001 | B1 |
6273884 | Altshuler et al. | Aug 2001 | B1 |
6277116 | Utely et al. | Aug 2001 | B1 |
6288498 | Cheng | Sep 2001 | B1 |
6308413 | Westerhof et al. | Oct 2001 | B1 |
6309352 | Oraevsky et al. | Oct 2001 | B1 |
6309387 | Eggers et al. | Oct 2001 | B1 |
6325797 | Stewart et al. | Dec 2001 | B1 |
6343400 | Massholder et al. | Feb 2002 | B1 |
6343933 | Montgomery et al. | Feb 2002 | B1 |
6352535 | Lewis et al. | Mar 2002 | B1 |
6353763 | George et al. | Mar 2002 | B1 |
6360116 | Jackson et al. | Mar 2002 | B1 |
6391023 | Weber et al. | May 2002 | B1 |
6400976 | Champeau | Jun 2002 | B1 |
6406157 | Audet | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6413268 | Hartman | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6433343 | Cimino et al. | Aug 2002 | B1 |
6436051 | Morris et al. | Aug 2002 | B1 |
6461567 | Hearst et al. | Oct 2002 | B1 |
6462070 | Hasan et al. | Oct 2002 | B1 |
6471716 | Pecukonis | Oct 2002 | B1 |
6482204 | Lax et al. | Nov 2002 | B1 |
6487447 | Weimann et al. | Nov 2002 | B1 |
6493940 | Westerhof et al. | Dec 2002 | B2 |
6494900 | Salansky et al. | Dec 2002 | B1 |
6497702 | Bernaz | Dec 2002 | B1 |
6500141 | Irion et al. | Dec 2002 | B1 |
6508813 | Altshuler | Jan 2003 | B1 |
6511475 | Altshuler et al. | Jan 2003 | B1 |
6514243 | Eckhouse et al. | Feb 2003 | B1 |
6517532 | Altshuler et al. | Feb 2003 | B1 |
6533775 | Rizoiu et al. | Mar 2003 | B1 |
6558653 | Andersen et al. | May 2003 | B2 |
6572637 | Yamazaki et al. | Jun 2003 | B1 |
6594905 | Furst et al. | Jul 2003 | B2 |
6602245 | Thiberg | Aug 2003 | B1 |
6612819 | Furst et al. | Sep 2003 | B1 |
6618620 | Freundlich et al. | Sep 2003 | B1 |
6623430 | Slayton et al. | Sep 2003 | B1 |
6632002 | Chubb et al. | Oct 2003 | B1 |
6637877 | Hartley et al. | Oct 2003 | B1 |
6662054 | Kreindel et al. | Dec 2003 | B2 |
6663620 | Altshuler et al. | Dec 2003 | B2 |
6676655 | McDaniel | Jan 2004 | B2 |
6702808 | Kreindel | Mar 2004 | B1 |
6704587 | Kumar et al. | Mar 2004 | B1 |
6708060 | Avrahami et al. | Mar 2004 | B1 |
6723092 | Brown et al. | Apr 2004 | B2 |
D490156 | Fischer et al. | May 2004 | S |
D490526 | Jonsen | May 2004 | S |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6758845 | Weckwerth et al. | Jul 2004 | B1 |
6761729 | Babaev | Jul 2004 | B2 |
6770069 | Hobart et al. | Aug 2004 | B1 |
6780838 | Lipton et al. | Aug 2004 | B2 |
6795728 | Chornenky | Sep 2004 | B2 |
RE38634 | Westerhof et al. | Oct 2004 | E |
6887260 | McDaniel | May 2005 | B1 |
6889090 | Kreindel | May 2005 | B2 |
6918907 | Kelly et al. | Jul 2005 | B2 |
6997923 | Anderson et al. | Feb 2006 | B2 |
7006874 | Knowlton et al. | Feb 2006 | B2 |
7013179 | Carter et al. | Mar 2006 | B2 |
7022121 | Stern et al. | Apr 2006 | B2 |
7052493 | Vaska et al. | May 2006 | B2 |
7077840 | Altshuler et al. | Jul 2006 | B2 |
7115123 | Knowlton et al. | Oct 2006 | B2 |
7115124 | Xiao | Oct 2006 | B1 |
7153298 | Cohen | Dec 2006 | B1 |
7204832 | Altshuler et al. | Apr 2007 | B2 |
7234239 | Saito et al. | Jun 2007 | B2 |
7266414 | Cornelius et al. | Sep 2007 | B2 |
7275819 | Bleau | Oct 2007 | B2 |
7278991 | Morris et al. | Oct 2007 | B2 |
7416550 | Protsenko et al. | Aug 2008 | B2 |
7601149 | DiCarlo et al. | Oct 2009 | B2 |
7771419 | Carmel et al. | Aug 2010 | B2 |
7824394 | Manstein | Nov 2010 | B2 |
7935107 | Altshuler et al. | May 2011 | B2 |
7963985 | Minamoto et al. | Jun 2011 | B2 |
8021360 | Dunning et al. | Sep 2011 | B2 |
8109927 | Kelly et al. | Feb 2012 | B2 |
8135475 | Kreindel et al. | Mar 2012 | B2 |
8157807 | Ferren et al. | Apr 2012 | B2 |
8202268 | Wells et al. | Jun 2012 | B1 |
8206381 | Lischinsky et al. | Jun 2012 | B2 |
8235989 | Palanker et al. | Aug 2012 | B2 |
8506564 | Long et al. | Aug 2013 | B2 |
20010007068 | Ota et al. | Jul 2001 | A1 |
20020058936 | Avrahami et al. | May 2002 | A1 |
20020104543 | Hollander et al. | Aug 2002 | A1 |
20020120256 | Furuno et al. | Aug 2002 | A1 |
20020120260 | Morris et al. | Aug 2002 | A1 |
20020120261 | Morris et al. | Aug 2002 | A1 |
20020128641 | Underwood et al. | Sep 2002 | A1 |
20020143373 | Courtnage et al. | Oct 2002 | A1 |
20020147384 | Uchikubo | Oct 2002 | A1 |
20020183245 | Hasan et al. | Dec 2002 | A1 |
20020190337 | House et al. | Dec 2002 | A1 |
20020198575 | Sullivan | Dec 2002 | A1 |
20030018255 | Martin et al. | Jan 2003 | A1 |
20030032900 | Ella | Feb 2003 | A1 |
20030032950 | Altshuler et al. | Feb 2003 | A1 |
20030055414 | Altshuler et al. | Mar 2003 | A1 |
20030097162 | Kreindel | May 2003 | A1 |
20030109871 | Johnson et al. | Jun 2003 | A1 |
20030135250 | Lauman et al. | Jul 2003 | A1 |
20030139790 | Ingle et al. | Jul 2003 | A1 |
20030195494 | Altshuler et al. | Oct 2003 | A1 |
20030199946 | Gutwein | Oct 2003 | A1 |
20040010250 | Manna et al. | Jan 2004 | A1 |
20040010298 | Altshuler et al. | Jan 2004 | A1 |
20040030227 | Littrup et al. | Feb 2004 | A1 |
20040064167 | Berry et al. | Apr 2004 | A1 |
20040127793 | Mendlein et al. | Jul 2004 | A1 |
20040133251 | Altshuler et al. | Jul 2004 | A1 |
20040143308 | Lundahl et al. | Jul 2004 | A1 |
20040147984 | Altshuler et al. | Jul 2004 | A1 |
20040167501 | Island et al. | Aug 2004 | A1 |
20040181216 | Kelly et al. | Sep 2004 | A1 |
20040186466 | Chornenky | Sep 2004 | A1 |
20040193234 | Butler | Sep 2004 | A1 |
20040210214 | Knowlton | Oct 2004 | A1 |
20040236320 | Protsenko et al. | Nov 2004 | A1 |
20040260210 | Ella et al. | Dec 2004 | A1 |
20040267252 | Washington et al. | Dec 2004 | A1 |
20050015042 | Sun et al. | Jan 2005 | A1 |
20050043653 | Trimmer et al. | Feb 2005 | A1 |
20050049543 | Anderson et al. | Mar 2005 | A1 |
20050075573 | Park et al. | Apr 2005 | A1 |
20050137654 | Hoenig et al. | Jun 2005 | A1 |
20050137655 | MacFarland et al. | Jun 2005 | A1 |
20050143793 | Korman et al. | Jun 2005 | A1 |
20050147137 | Slatkine | Jul 2005 | A1 |
20050177139 | Yamazaki et al. | Aug 2005 | A1 |
20050288680 | Ingle et al. | Dec 2005 | A1 |
20060036300 | Kreindel | Feb 2006 | A1 |
20060095096 | DeBenedictis et al. | May 2006 | A1 |
20060122509 | Desilets | Jun 2006 | A1 |
20060149343 | Altshuler et al. | Jul 2006 | A1 |
20060184024 | Da Silva et al. | Aug 2006 | A1 |
20060200213 | McDaniel | Sep 2006 | A1 |
20060206173 | Gertner et al. | Sep 2006 | A1 |
20060224217 | Burgmann et al. | Oct 2006 | A1 |
20060231568 | Lynn et al. | Oct 2006 | A1 |
20060247741 | Hsu et al. | Nov 2006 | A1 |
20060259102 | Slatkine | Nov 2006 | A1 |
20060271028 | Altshuler et al. | Nov 2006 | A1 |
20070016117 | Sliwa et al. | Jan 2007 | A1 |
20070038206 | Altshuler et al. | Feb 2007 | A1 |
20070088348 | Kochamba | Apr 2007 | A1 |
20070093798 | Debenedictis et al. | Apr 2007 | A1 |
20070106349 | Karni et al. | May 2007 | A1 |
20070129771 | Kurtz et al. | Jun 2007 | A1 |
20070142881 | Hennings | Jun 2007 | A1 |
20070179482 | Anderson | Aug 2007 | A1 |
20070191821 | Boxer Wachler | Aug 2007 | A1 |
20070197895 | Nycz et al. | Aug 2007 | A1 |
20070198004 | Altshuler et al. | Aug 2007 | A1 |
20070206275 | Hemmer et al. | Sep 2007 | A1 |
20070213696 | Altshuler et al. | Sep 2007 | A1 |
20070232962 | Zumeris et al. | Oct 2007 | A1 |
20070239077 | Azhari et al. | Oct 2007 | A1 |
20070239142 | Altshuler et al. | Oct 2007 | A1 |
20070239143 | Altshuler et al. | Oct 2007 | A1 |
20070271714 | Adam et al. | Nov 2007 | A1 |
20080051680 | Luebcke | Feb 2008 | A1 |
20080071334 | Hoenig et al. | Mar 2008 | A1 |
20080082090 | Manstein | Apr 2008 | A1 |
20080114255 | Schwartz et al. | May 2008 | A1 |
20080123238 | Campos et al. | May 2008 | A1 |
20080125658 | Lee et al. | May 2008 | A1 |
20080139901 | Altshuler et al. | Jun 2008 | A1 |
20080154247 | Dallarosa et al. | Jun 2008 | A1 |
20080183167 | Britva et al. | Jul 2008 | A1 |
20080215124 | Wagenaar Cacciola et al. | Sep 2008 | A1 |
20080221504 | Aghion | Sep 2008 | A1 |
20080294153 | Allshuler et al. | Nov 2008 | A1 |
20080306476 | Hennings et al. | Dec 2008 | A1 |
20090036953 | Gustavsson | Feb 2009 | A1 |
20090043293 | Pankratov et al. | Feb 2009 | A1 |
20090048514 | Azhari et al. | Feb 2009 | A1 |
20090112205 | McGill et al. | Apr 2009 | A1 |
20090119834 | Kneale et al. | May 2009 | A1 |
20090143673 | Drost et al. | Jun 2009 | A1 |
20090171341 | Pope et al. | Jul 2009 | A1 |
20090182315 | Zigan et al. | Jul 2009 | A1 |
20090192503 | Epshtein et al. | Jul 2009 | A1 |
20090234341 | Roth | Sep 2009 | A1 |
20090234342 | Ely et al. | Sep 2009 | A1 |
20090240310 | Kennedy | Sep 2009 | A1 |
20090275865 | Zhao et al. | Nov 2009 | A1 |
20090299361 | Flyash et al. | Dec 2009 | A1 |
20100063565 | Beerwerth et al. | Mar 2010 | A1 |
20100185193 | Kreindel | Jul 2010 | A1 |
20100185194 | Kreindel | Jul 2010 | A1 |
20100198134 | Eckhouse | Aug 2010 | A1 |
20100274329 | Bradley et al. | Oct 2010 | A1 |
20110112405 | Barthe et al. | May 2011 | A1 |
20110137386 | Kreindel | Jun 2011 | A1 |
20110166559 | Eckhouse et al. | Jul 2011 | A1 |
20110196363 | Kreindel | Aug 2011 | A1 |
20120143270 | Mehta | Jun 2012 | A1 |
20120290023 | Boyden et al. | Nov 2012 | A1 |
20130289679 | Eckhouse et al. | Oct 2013 | A1 |
Number | Date | Country |
---|---|---|
2495005 | Feb 2004 | CA |
1078383 | Nov 1993 | CN |
0528055 | Feb 1993 | EP |
0743029 | Jul 2002 | EP |
0824019 | Nov 2002 | EP |
2125986 | Aug 1982 | GB |
2202442 | Sep 1988 | GB |
04299998 | Oct 1992 | JP |
06113920 | Apr 1994 | JP |
11132843 | Dec 1999 | JP |
2003034630 | Feb 2003 | JP |
WO-8302389 | Jul 1983 | WO |
WO-9321992 | Nov 1993 | WO |
WO-9909143 | Feb 1999 | WO |
WO-9909143 | Feb 1999 | WO |
WO-9934867 | Jul 1999 | WO |
WO-02078644 | Oct 2002 | WO |
WO-02078644 | Oct 2002 | WO |
WO-03039367 | May 2003 | WO |
WO-03039367 | May 2003 | WO |
WO-2006128034 | Nov 2006 | WO |
Entry |
---|
Acne Clearance, LHE Clinical Casebook, Radiancy: Lighting the Future of Skin Care, © 2002. |
Acne Star web page, describing “How to use get rid of Acne Treatment”, printed May 5, 2005. |
Acne Star web page, describing Clinical Studies, “The Treatment of acne vulgaris with a novel device that uses Gallium—Nitride diode”, printed May 5, 2005. |
Acne Star web page, describing Clinical Studies, “The Treatment of acne vulgaris with a novel device that uses Gallium—Nitride diode light”, printed May 5, 2005. |
Aesthetic Buyers Guide: The Leading Cosmetic Practice Resource, Jan./Feb. 2004, vol. 7, No. I. |
Bollen, CM. et al., “Full- versus partial-mouth disinfection in the treatment of periodontal infections. A pilot study: long-tenn microbiological observations”, J Clin Periodontol Oct. 1996;23(10):960-70 (Abstract). |
Bollen, CM. et al., “Full- versus partial-mouth disinfection in the treatment of periodontal infections. A pilot study: long-term microbiological obervations”. J Clin Periodontol Oct. 1996;23(10):960-70 (Abstract). |
Bollen, CM. et al., The effect of a one-stage full-mouth disinfection on different intra—0ral niches Clinical and microbiological observations•. J Clin Periodontol Jan. 1998;25(1 ):56-66 (Abstract). |
Bollen, CM. et al., “The effect of a one-stage full-mouth disinfection on different intra-oral niches. Clinical and microbiological observations”, J Clin Periodontol Jan. 1998;25(1 ):56-66 (Abstract). |
Calderhead, R. Glen, “The Photobiology of LED Phototherapy”. |
Calder1-lead R. Glen, “The Photobiology of LED Photothcrapy”. |
Charakida et al., “Phototherapy in the Treatment of Acne Vulgaris, What is the Role'?”, Am. J. Clin Dermatol 2004: 5(4):211-216. |
Cohen L.R., “What causes bad breath?”, University of Toronto; webpage (printed before Nov. 2, 2004). |
Cohen LR., “What causes bad breath?”, University of Toronto; webpage (printed before Nov. 2, 2004). |
Coventry et al. (2000) “ABC of oral health: Periodontal disease” British Medical Journal, 321, 36-39. |
De Soete, M. et al .. One-stage full-mouth disinfection. Long-term microbiological results analyzed by checker board DNA-DNA hybridization•, J Periodontol Mar. 2001; 72(3):374-82 (Abstract). |
De Soete, M. et al., “One-stage full-mouth disinfection. Long-term microbiological results analyzed by checker board DNA-DNA bybridization”, J Periodontol Mar. 2001; 72(3):674-82 (Abstract). |
Elman M. et al., “The effective treatment of acne vulgaris by a high-intensity, narrow bank 405-420 nm light source”, Cosmetic & Laser Ther 2003; 5: 111-116. |
Elman M. et al., The effective treatment of acne vulgaris by a high-intensity, narrow bank 405-420 nm light source•, Cosmetic & Laser Ther 2003; 5: 111-116. |
Flow Control Network web page, “Mini Diaphragm Pumps for Precision Dispensing” by Ping Lin, printed Aug. 2, 2005. |
Friedberg J.S. et al., “Antibody-Targeted Photolysis Bacteriocidal Effects of Sn (IV) Chlorin e6- 0extran-Monoclonal Antibody Conjugates”, Annals New York Academy of Sciences 618:383-393, 1991. |
Friedberg JS et al., “Antibody-Targeted Photolysis Bacteriocidal Effects of Sn (IV) Chlonn e6-Dextran-Monoclonal Antibody Conjugates”, Annals New York Academy of Sciences 618:383-393, 1991. |
Greenstein G., Full-mouth therapy versus individual quadrant root planning: a critical commentary, J Periodontol Jul. 2002;73(7):797-812 (Abstract). |
Greenstein G., Full-mouth therapy versus individual quadrant root planning: a critical commentary, JPeriodontol Jul. 2002;73(7):797-812 (Abstract). |
Guidelines for Limiting Exposure to Time-Varying Electric, Magnetic, and Electromagnetic Fields (Up to 300 GHz), International Commission on Non-Ionizing Radiation Protection, ICNIRP Guidelines, Apr. 1998, vol. 7 4, No. 4, pp. 494-522. |
Hamblin, M. et al., “Rapid Control of Wound Infections by Targeted Photodynamic Therapy Monitored by In Vivo Bioluminescence Imagining”, Photochemistry and Photobiology, 2002, 75(1 ): 51-57. |
Hamblin, M. et al., Rapid Control of Wound Infections by Targeted Photodynamic Therapy Monitored by In Vivo Bioluminescence Imagining•, Photochemistry and Photobiology, 2002, 75(1): 51-57. |
Komerik et al. (2003) “In vivo killing of Porphyromonas gingivalis by toluidine blue-mediated photosensitization in an animal model” Antimicrobial Agents and Chemotherapy, 47(3), 932-940. |
Krespi, et al. (2005) “Lethal photosensitization of oral pathogens via red-filtered halogen lamp” Oral Diseases, 11(S1), 92-95. |
Krespi, et al. (2005) “Lethal photosensitization of oral pathogens via red-filtered halogen larnp” Oral Diseases, 11(S1 ), 92-95. |
Malik, Z. et al., “New Trends in Photobiology (Invited Review) Bactericidal Effects of Photoactivated Porphyrins—An Alternative Approach to Antimicrobial Drugs”, Journal of Photochemistry and Photobiology, B: Biology, 5—1—1990}—281-293. |
Malik, Z. et al., “New Trends in Photobiology (Invited Review) Bactericidal Effects of Photoactivated Porphyrins • An Alternative Approach to Antimicrobial Drugs”, Journal of Photochemistry and Photobiology, B: Biology, 5 J.19901—281-293. |
Matevski D. et al., “Lethal photosensitization of periodontal pathogens by a red-filtered Xenon lamp in invitro”, J. Periodont. Res. 2003, 38:428-435. |
Matevski D. et al., “Lethal photosensitization of periodontal pathogens by a red-filtered Xenon lamp in invitro”, JPeriodont. Res. 2003. 38:428-435. |
Matevski D. et al., Sensitivity of Porphyromonas gingivalis to Light-Activated Toluidine Blue o•. University of Toronto, Faculty of Dentistry; Slide presentation (presented before Nov. 15, 2002). |
Matevski D. et al., “Sensitivity of Porphyromonas gingivalis to Light-Activated Toluidine Blue O”, University of Toronto, Faculty of Dentistry; Slide presentation (presented before Nov. 15, 2002). |
Meisel et al. (2005) Photodynamic therapy for periodontal diseases: State of the are• J. Photochem. Photobiol., 79, 159-170. |
Meisel etal. (2005) “Photodynamic therapy for periodontal diseases: State of the are” J. Photochem. Photobiol., 79, 159-170. |
Mongardini, C. et al., One stage full—versus partial-mouth disinfection in the treatment of chronic adult or generalized early—0nset periodontitis. I. Long-tenn clinical observations•, J Periodontol Jun. 1999;70(6):632-45—[Abstrac!). |
Mongardini, C. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized early-onset periodontitis. I. Long-term clinical observations”, J Periodontol Jun. 1999;70(6):632-45 1Abstrac!2. |
Morton C.A. et al., An open study to determine the efficacy of blue light in the treatment of mild to moderate acne: preliminary data (publication status unknown). |
Nakano et al. (2002) “Correlation between oral malodor and periodontal bacteria” Microbes Infect., 4(6), 679-683. |
Nakano et al. (2002) “Correlation between oral malodor and periodontal bacteria” Microbes Infect., 4(6). 679-683. |
Ondine Biopharma web page—printed Oct. 15, 2002. |
Papageorgiou ct al., “Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris”, British Journal of Dermatology 2000: 142: 973-978. |
Pharmaceutical description, Levulan® Kerastick *aminolevulinic acid I-IC!) for Topical Solution, 20'X. |
Pharmaceutical description, Levulan® Kerastick •aminolevulinic acid HCI) for Topical Solution, 20%. |
Quirynen, M. et al. Fuli- vs. partial-mouth disinfection in the treatment of periodontal infections: short-tennclinical and microbiological observations•. J Dent Res Aug. 1995;74(8):1459-67 (Abstract). |
Quirynen, M. et al. “Full- vs. partial-mouth disinfection in the treatment of periodontal infections: short-term clinical and microbiological observations”, J Dent Res Aug. 1995;74(8):1459-67 (Abstract). |
Quirynen, M. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized early-onset periodontitis. II. Long-term impact on microbial load”, J Periodontol Jun. 1999;70(6):646-56 (Abstract). |
Quirynen, M. et al., “The effect of a 1-stage full-mouth disinfection on oral malodor and microbial colonization of the tongue in periodontitis. A pilot study”, J Periodontol Mar. 1998;69(3):374-82 (Abstract). |
Quirynen, M. et al., “The intra-oral translocation of periodontopathogens jeopardises the outcome of periodontal therapy”, Journal of Clincial Periodontology, Jun. 2001, vol. 28, Issue 6, p. 499 (Abstract). |
Quirynen, M. et al., The role of chlorhexidine in the one-stage full-mouth disinfection treatment of patients with advanced adult periodontitis. Long-term clinical and microbiological observations•. J Clin Periodontol 2000 A1.IQ;27.{fil:579-89 J—Abstrac!). |
Quirynen, M. et al., “The role of chlorhexidine in the one-stage full-mouth disinfection treatment of patients with advanced adult periodontitis. Long-term clinical and microbiological observations”, J Clin Periodontol 2000 AP!JL2˜579-89 J—Abstrac—!). |
Quirynen. M. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized early-onset periodontitis. II. Long-term impact on microbial load”, J Periodontol Jun. 1999;70(6):646-56 J—Abstrac!2. |
Sanz et al. (2001) “Fundamentals of breath malodour” Journal of Contemporary Dental Practice, 2(4 ), 1-13. |
Sanz et al. (2001) “Fundamentals of breath malodour” Journal of Contemporary Dental Practice, 2(4), 1-13. |
Sarkar et al. (1993) “Lethal photosensitization of bacteria in subgingival plaque from patients with chronic periodontitis” J. Periodont. Res , 28, 204-21 O. |
Sarkar et al. (1993) “Lethal photosensitization of bacteria in subgingival plaque from patients with chronic periodontitis” J. Periodont. Res., 28, 204-210. |
Search results from Delphion web site, dated Nov. 22, 2005. |
Skin91 I .com web page regarding Peter Thomas Roth Clinical Acne Medication, acne treatment-Benzoyl Peroxide 5% pbp5, printed Apr. 19, 2005. |
Skin91 I .corn web page regarding Peter Thomas Roth Clinical Acne Medication, acne treatment-Benzoyl Peroxide 5% pbp5, printed Apr. 19, 2005. |
Soukos et al. (1998) “Targeted antimicrobial photochemotherapy”, Antimicrobial Agents and Chemotherapy 42( 10 ), 2595-2601. |
Soukos et al. (1998) “Targeted antimicrobial photochemotherapy”, Antimicrobial Agents and Chemotherapy 42(10), 2595-2601. |
Spire Awarded Contract for Ear Surgery Laser—Press Release Aug. 23, 2002. |
Temperatures.com web page, “Thermistor Temperature Sensors,” printed Aug. 2, 200. |
Temperatures.corn web page, “Thermistor Temperature Sensors,” printed Aug. 2, 200. |
Vandekerckhove, BN. et al., “Full- versus partial-mouth disinfection in the treatment of periodontal infections. Long-term clinical observations of a pilot study”, J Periodontol Dec. 1996;67(12):1251-9 (Abstract). |
Vandekerckhove, Bn. et al.. “Full—versus partial-mouth disinfection in the treatment of periodontal infections. Long-term clinical observations of a pilot study”, J Periodontol Dec. 1996;67(12):1251-9 (Abstract). |
Wainwright M., Photodynamic antimicrobial chemotherapy (PACT), Journal of Antimicrobial Chemotherapy (1198) 42. 13-28. |
Wilson (2005) “Lethal photosensitisation of oral bacteria and its potential application in the photodynamic therapy of oral infection” Photochem. Photobiol. Sci .. 3, 412-418. |
Wilson (2005) “Lethal photosensitisation of oral bacteria and its potential application in the photodynamic therapy of oral infection” Phorochem. Photobiol. Sci., 3, 412-418. |
Wilson et al. (1995) “Bacteria in supragingival plaque samples can be killed by low-power laser light in the presence of a photosensitizer” J. Appl. Bacteriol .. 78, 569-574. |
Wilson et al. (1995) “Bacteria in supragingival plaque samples can be killed by low-power laser light in the presence of a photosensitizer” J. Appl. Bacteriol., 78, 569-574. |
Wood, et al. (1999) “An in vitro study of the use of photodynamic therapy for the treatment of natural oral plaque biolfilms formed in vivo” J. Photochem. Photogiol. B: Biol .. 50, 1-7. |
Wood, et al. (1999) “An in vitro study of the use of photodynamic therapy for the treatment of natural oral plaque biofilms formed in vivo” J. Photochem. Photogiol. B: Biol., 50, 1-7. |
www.lightbioscience.com web page, Gentle Waves Cosmcceuticals, printed Jul. 29, 200. |
www.lightbioscience.com web page, Gentle Waves LED Photomodulation Fact Sheet, printed Jul. 29, 2005. |
www.lightbioscience.com web page, GentleWaves Cosmeceuticals, printed Jul. 29, 200. |
www.lightbioscience.com web page, GentleWaves LED Photomodulation Fact Sheet, printed Jul. 29, 2005. |
PCT/IL04/01119 International Search Report. |
Number | Date | Country | |
---|---|---|---|
20100016761 A1 | Jan 2010 | US |
Number | Date | Country | |
---|---|---|---|
61081110 | Jul 2008 | US |